A new strategic movement in the hot CRISPR field: CRISPR Therapeutics ramps up its leadership team with Samarth Kulkarni as its new Chief Business Officer and Michael Bruce as Senior Vice President to moderate program portfolio and alliance management. In the meantime, CRISPR’s main competitor EditasMedicine procured €108M to accelerate its CRISPR-based therapies in clinical state.
CRISPR Therapeutics is one of the four leading companies currently fighting within the CRISPR Therapeutical revolution. The biopharmaceutical company, headquartered in Basel, was cofounded by Emmanuelle Charpentier, co-discoverer of the CRISPR-cas9 technology and one of the most influential people in European biopharma. Today, two new executives have joined the team: Dr. Samarth Kulkarni and Dr. Michael Bruce.
Dr. Kulkarni comes from management consulting giant McKinsey, where he was a partner and had a leading role in the pharmaceutical and medical products practice. The Ph.D. in bioengineering and nanotechnology co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations.